tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

VERV Stock Latest News

Verve Therapeutics’ (VERV) Gene-Editing Therapies Could Be a Game Changer
Market NewsVerve Therapeutics’ (VERV) Gene-Editing Therapies Could Be a Game Changer
2M ago
VERV
Levi & Korsinsky LLP Notifies Shareholders of Verve Therapeutics, Inc.(VERV) of a Class Action Lawsuit and an Upcoming Deadline
PremiumClass Action
Levi & Korsinsky LLP Notifies Shareholders of Verve Therapeutics, Inc.(VERV) of a Class Action Lawsuit and an Upcoming Deadline
2M ago
VERV
Verve Therapeutics price target lowered to $29 from $30 at Canaccord
PremiumThe Fly
Verve Therapeutics price target lowered to $29 from $30 at Canaccord
3M ago
VERV
Verve Therapeutics reports Q2 EPS (59c), consensus (68c)
PremiumThe Fly
Verve Therapeutics reports Q2 EPS (59c), consensus (68c)
3M ago
VERV
Verve Therapeutics Expands Board with Two New Members
PremiumCompany Announcements
Verve Therapeutics Expands Board with Two New Members
4M ago
8K
VERV
Verve Therapeutics appoints Nia Tatsis, Jodie Morrison to board
PremiumThe FlyVerve Therapeutics appoints Nia Tatsis, Jodie Morrison to board
4M ago
QTTB
VERV
Verve Therapeutics Announces New Chief Scientific Officer
Premium
Company Announcements
Verve Therapeutics Announces New Chief Scientific Officer
5M ago
8K
VERV
Verve Therapeutics CSO Andrew Bellinger steps down, Troy Lister to succeed
Premium
The Fly
Verve Therapeutics CSO Andrew Bellinger steps down, Troy Lister to succeed
5M ago
VERV
Verve Therapeutics COO buys $475.8K in common stock
PremiumThe Fly
Verve Therapeutics COO buys $475.8K in common stock
6M ago
VERV
Verve Therapeutics’ Financial Outlook Threatened by CRISPR Patent Disputes
PremiumCompany Announcements
Verve Therapeutics’ Financial Outlook Threatened by CRISPR Patent Disputes
6M ago
VERV
Verve Therapeutics reports Q1 EPS (59c), consensus (71c)
PremiumThe Fly
Verve Therapeutics reports Q1 EPS (59c), consensus (71c)
6M ago
VERV
Verve Therapeutics announces dosing of first patient in VERVE-102 trial
PremiumThe Fly
Verve Therapeutics announces dosing of first patient in VERVE-102 trial
6M ago
VERV
Verve Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe FlyVerve Therapeutics initiated with a Buy at H.C. Wainwright
7M ago
VERV
Verve Therapeutics price target lowered to $40 from $56 at Stifel
Premium
The Fly
Verve Therapeutics price target lowered to $40 from $56 at Stifel
7M ago
VERV
Citi sees limited readthrough for Beam Therapeutics from VERVE-101 trial pause
Premium
The Fly
Citi sees limited readthrough for Beam Therapeutics from VERVE-101 trial pause
7M ago
BEAM
VERV
RBC remains buyer of Verve Therapeutics after enrollment pause
PremiumThe Fly
RBC remains buyer of Verve Therapeutics after enrollment pause
7M ago
VERV
Verve Therapeutics (NASDAQ:VERV) Plunges on Trial Halt
PremiumMarket News
Verve Therapeutics (NASDAQ:VERV) Plunges on Trial Halt
7M ago
VERV
Verve Therapeutics down 33% at $8.50 after pausing Heart-1 trial of VERVE-101
PremiumThe Fly
Verve Therapeutics down 33% at $8.50 after pausing Heart-1 trial of VERVE-101
7M ago
VERV
Verve Therapeutics pauses enrollment in Heart-1 trial of VERVE-101
PremiumThe Fly
Verve Therapeutics pauses enrollment in Heart-1 trial of VERVE-101
7M ago
VERV
Verve Therapeutics price target lowered to $30 from $32 at Canaccord
PremiumThe FlyVerve Therapeutics price target lowered to $30 from $32 at Canaccord
8M ago
VERV
Verve Therapeutics reports Q4 EPS (69c), consensus (82c)
Premium
The Fly
Verve Therapeutics reports Q4 EPS (69c), consensus (82c)
8M ago
VERV
Verve Therapeutics director buys $18M in common stock
Premium
The Fly
Verve Therapeutics director buys $18M in common stock
11M ago
VERV

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >